X

Annals of Oncology

Annals of Oncology
Zolbetuximab Plus EOX Versus EOX Alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma

This phase II study evaluates clinical outcomes of zolbetuximab + EOX versus EOX alone in advanced CLDN18.2+ gastric cancer.

Annals of Oncology
05/01/2021
ESMO Recommendations on the Standard Methods to Detect RET Fusions and Mutations in Daily Practice and Clinical Research

New selective RET inhibitors have activity and favorable toxicity profiles in RET-altered solid tumors.

Annals of Oncology
03/01/2021
Checkpoint Inhibitor Therapy for Skin Cancer May be Safe in Patients With Asymptomatic COVID-19

An ongoing area of uncertainty during the SARS-CoV-2 pandemic is the safety of ICI therapy for cancer, and the theoretical possibility of exacerbated irAEs secondary to COVID-19 inflammatory pathol

Annals of Oncology
02/16/2021
Subscribe to Annals of Oncology

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39